Figure 2.
Combination of dasatinib and temsirolimus mTOR inhibitor elicit potent cell cycle arrest and leukemia cell killing in human T-ALL. (A) Jurkat. (B) MOLT-4. (C) PF-382. Dose-response curves following single drug and combination therapy (i). Dasatinib and temsirolimus after 72 hours of treatment and assessed by CellTiter-Glo. Combination indexes for ED50 concentrations are shown. Green lines highlight synergistic combination treatments. Cell proliferation assessed by EdU/PI staining (ii). Apoptosis assessed by AnnexinV/PI staining (iii). Error bars ± SEM. n = 3 samples/data point. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001 in comparing single vs combination treated cells (i) or in assessing differences in overall percentages of cells in S-phase or AnnexinV+/PI+ cells by Student 2-tailed t test (ii and iii).

Combination of dasatinib and temsirolimus mTOR inhibitor elicit potent cell cycle arrest and leukemia cell killing in human T-ALL. (A) Jurkat. (B) MOLT-4. (C) PF-382. Dose-response curves following single drug and combination therapy (i). Dasatinib and temsirolimus after 72 hours of treatment and assessed by CellTiter-Glo. Combination indexes for ED50 concentrations are shown. Green lines highlight synergistic combination treatments. Cell proliferation assessed by EdU/PI staining (ii). Apoptosis assessed by AnnexinV/PI staining (iii). Error bars ± SEM. n = 3 samples/data point. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001 in comparing single vs combination treated cells (i) or in assessing differences in overall percentages of cells in S-phase or AnnexinV+/PI+ cells by Student 2-tailed t test (ii and iii).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal